Quantifying ADC Complexity: Anti-ID Antibody Generation and Multi-Analyte PK Assay Design

Please register via: https://us06web.zoom.us/webinar/register/WN_vBwQEYehSTSu8Zqx_W_k6Q

Webinar Title： Quantifying ADC Complexity: Anti-ID Antibody Generation and Multi-Analyte PK Assay Design

Abstract:

Antibody–drug conjugates (ADCs) combine the targeting specificity of monoclonal antibodies with the cytotoxic potency of small-molecule payloads and have rapidly emerged as an important class of targeted therapeutics. However, the structural complexity of ADCs and their dynamic in vivo processing pose significant challenges for pharmacokinetic (PK) and bioanalytical measurements. Accurate quantification of total antibody, conjugated antibody, and payload-related species requires carefully designed bioanalytical strategies and highly specific detection reagents.

In this seminar, we will first introduce the evolving landscape of ADC therapeutics and discuss key bioanalytical challenges associated with ADC PK characterization. We will then present Yurogen’s SMAB platform for generating high-specificity anti-idiotype (anti-ID) monoclonal antibodies targeting the Fab region or payload-associated epitopes, enabling the development of robust ligand-binding assays for ADC bioanalysis.

Finally, we will discuss current industry practices for ADC bioanalytical method development, including commonly used ligand-binding assays and complementary analytical platforms for PK assessment. Together, this seminar will highlight how tailored reagent development and optimized bioanalytical strategies can support accurate ADC PK measurement and facilitate the advancement of ADC therapeutics.

Speakers:

Dr. Hao Cheng received his B.S. from Wuhan University and his Ph.D. in Microbiology and Immunology from Dartmouth College. He currently serves as Chief Scientific Officer (CSO) of Yurogen Biosystems, an Abclonal Technologies subsidiary, where he leads the development of antibody discovery platforms and oversees R&D and production operations.

Dr. Cheng specializes in antibody discovery and engineering, with extensive experience across multi-species antibody platforms, including human, rabbit, mouse, and camelid antibodies, as well as antibody optimization and AI-assisted antibody design. His work spans immunology, therapeutic antibody engineering, tumor immunology, and translational medicine.

He has authored 13 peer-reviewed publications and filed 28 invention patents, 13 of which have been granted.

Dr. Jim Chen, an immunologist by training, with a PhD from the Chinese Academy of Sciences and postdoctoral training at the University of Chicago. Professional experience spans the University of Chicago, Teva Pharmaceuticals, AstraZeneca, and CRO leadership roles in both China and the United States. Expertise includes regulated bioanalysis, translational science, and biomarker strategy across pharmacology, preclinical GLP toxicology and clinical studies.